Friday 6 November 2026
Export EVH’s income statement to Excel — free account
Evolent Health, Inc
EVH Healthcare Health Information Services
Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024.
- Revenue
- +51.3%
- EPS
- +12.5%
- Free cash flow
- +179.8%
- Total debt
- −8.09%
Quarter to September 2026, against a year earlier
4.60
0.06
+1.32%
Follow EVH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 5 | 4 |
+8 more TTM periods Free account |
| (83.57%) | (79.90%) | (80.15%) | (81.81%) | ||
| (23.00%) | (23.05%) | (23.55%) | (26.08%) | ||
ROIC |
(22.87%) | (22.06%) | (21.76%) | (21.22%) | |
Return on Tangible Assets |
(242.12%) | (256.04%) | (264.31%) | (286.98%) | |
Average Days of Receivables |
68.98 | 78.17 | 60.71 | 60.28 | |
Free Cash Flow per Share |
0.32 | 0.22 | 0.01 | 0.04 | |
Free Cash Flow |
36.66 | 24.34 | 1.40 | 4.76 | |
Capital Expenditures |
(28.22) | (29.98) | (31.90) | (34.09) | |
| Other line items | |||||
Cash ROIC |
2.45% | 1.64% | 0.09% | 0.30% | |
Accounts Receivable Turnover |
5.65 | 5.19 | 5.07 | 5.18 | |
Accounts Payable Turnover |
36.22 | 32.05 | 24.96 | 18.95 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
6.93 | 8.17 | 15.25 | 14.78 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
12.27% | 13.92% | 15.79% | 16.20% | |
Share Based Compensation of Revenue |
1.84% | 2.05% | 2.08% | 2.12% | |
Interest Coverage |
(6.23) | (6.18) | (6.55) | (7.14) | |
Operating CF/Net income |
(0.13) | (0.11) | (0.06) | (0.07) | |
Depreciation/Fixed assets |
0.00 | 6.44 | 6.50 | 6.54 | |
Capex/Depreciation |
0.00 | (0.06) | (0.06) | (0.06) | |
Revenue per Share |
20.72 | 18.63 | 16.88 | 16.43 | |
Operating CF per Share |
0.57 | 0.48 | 0.30 | 0.34 | |
Capex per Share |
(0.25) | (0.27) | (0.29) | (0.30) | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026